Dimension Therapeutics Spurns Regenxbio for Sweeter Ultragenyx Offer

Dimension Therapeutics said today it has terminated earlier plans to be acquired by Regenxbio for $85 million after accepting a sweeter, approximately $151 million acquisition offer from Ultragenyx Pharmaceutical—ending the prospect of a bidding war for the gene therapy developer.Ultragenyx’s offer amounts to $6 per share cash, 50 cents (approximately 9%) above its initial roughly $138 million offer for Dimension disclosed on September 18 .Dimension said its board agreed to halt its